Real-time PCR (qPCR) and Digital PCR (dPCR) Market (By Technology: Digital, Quantitative; By Product: Instruments, Reagents and Consumables, Software & Services; By Application: Research [Forensic and Others], Clinical [Pathogen Testing, Oncology Testing, Blood Screening, Others) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

According to Acumen Research and Consulting, the global Real-time PCR (qPCR) & Digital PCR (dPCR) market is expected to grow at noteworthy CAGR around 8.1 % throughout the forecast period and reach around US$ 4.2 billion by 2026.

In order to amplify or make more copies of the deoxyribonucleic acid (DNA) sequence of interest, polymerase chain reaction technology (PCR) is utilized. In different applications the polymerass chains reaction (PCR) technology covers the diagnosis of hereditary diseases, genes, paternity testing, infectious disease detection, and forensical sciences. Polymerase chain reaction (PCR) technology is used. Two key types of polymerase chain reaction (PCR) technologies are digital PCR (dPCR) and quantitative PCR (qPCR). Digital PCR is a relatively new technique used by the molecular counting protocol for DNA amplification and quantification. Effective PCR is primary in the differentiation of allel expression, the tracking of virus infection in individual cells, the quantification of cancer genes, and the detection in the circulating blood of fetal DNA. DPCR's key advantage is that its responsiveness and the preparation of standard curves are not necessary. Effective PCR (Quantitative PCR), also known as the PCR (qPCR) simultaneously computes PCR amplification with the reaction. qPCR does not require post amplification processing that reduces the analytical process turnaround time and the risk of amplified DNA or RNA contamination.

The report provides analysis of global Real-time PCR (qPCR) & Digital PCR (dPCR) market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.

Market Dynamics

The key growth drivers are expected to be the higher occurrence of target disease and swift technological developments such as high performance development and advanced dPCR and qPCR systems.

According to the WHO, cancer was one of the world's leading death causes in 2018, accounting for 9.6 million deaths. WHO estimates HIV infection was reached by 36.9 million people in 2017. Infectious diseases were also reported to be one of the world's leading causes of death in 2016. Cases of these diseases are expected to increase and will soon lead the market.

In addition, PCR manufacturers are continuing their efforts to develop new systems and kits to be used in molecular testing. QIAGEN N.V., for example, in January 2019 announced its plans for the development of dPCR systems for the next generation, scheduled for launch in 2020. Compared with current digital PCR platforms, new systems should offer very automated workflows and faster turnaround time, which are likely to provide a major competitive advantage for the company.

Furthermore, a wide range is expected to promote the adoption of the qPCR and dPCR technologies in a variety of science disciplines. In both basic and diagnostics research, technologies have extensive applications. They were widely used in areas like human genetic testing, forensic research, pathogen detection and testing for infectious diseases. A further fueling of the market is expected to expand application in food microbiology and veterinary industry, among other industries.

Technology Outlook

The technology-driven market is divided up into quantitative and digital PCRs (qPCR) and Real-time PCRs (dPCRs). In 2018, Quantitative PCR held the highest value market share. The segment is projected to be driven by continuous demand in areas such as gene expression analysis, genetic variation analysis, and genotyping, as well as by the increased focus on developing point of care (PoC) platforms. Digital PCR is a method for the testing of nucleic acids in the next generation. These systems are superior to other PCR-based approaches that are expected to contribute to the segment's strong growth during the forecast period.

Product Stance

The market is divided into consumer and reagent products, instruments, and software and services on the basis of the product. In terms of its value in 2018, the consumables and reagents were the leading segment. Compared to other segments, the segment is expected to be at strong growth due to the launch of new PCR test kits.

In October 2017, for example, the Official Analysis Method for Salmonella Species in Row Meat certified by AOAC INTERNATIONAL as the independent organization developing standards Biomotive Laboratories iQ-Check (Real-Time PCR Kit). Validation provided the opportunity for the kit to be used in a range of meat industry industrial applications.

Application Snapshot

On the basis of application, the market is segmented into research, clinical, forensic, and others. Research application was the dominant segment in 2018. qPCR and dPCR systems are widely used for research applications such as stem cell research and genetic disease and oncology research.

Functionality such as enhanced speed and faster turnarounds is the broad use of these systems. Due to increasing use of automated processes, the clinical application segment estimates to record over 8.5% of the fastest CAGR in the forecast period.

Regional Outlook

The regional segment was led by North America in 2018, attributed to the launch of PCR manufacturers ' new systems and test kit. Thermo Fisher Scientific Inc., for example, introduced VetMAX MastiType in September 2018, a qPCR-based test package which serves to quickly detect mastitis pathogen in milk stocks. In addition, the strong presence of leading PCR producers and the growing demand for rapid diagnostic testing in this area will also lead to regional growth during the forecast period.

In the forecast period Asia Pacific will probably be the quickest witness of a CAGR of over 11 %. The patient pool is projected to increase as a result of the high prevalence of chronic and infectious disease and the increasing awareness of early diagnosis among patients, which will in turn drive the market growth of PCR products.

Market Segmentation

Global Real-time PCR (qPCR) & Digital PCR (dPCR) Market, By Technology

• Digital
• Quantitative

Global Real-time PCR (qPCR) & Digital PCR (dPCR) Market, By Product

• Instruments
• Reagents and Consumables
• Software & Services

Global Real-time PCR (qPCR) & Digital PCR (dPCR) Market, By Application

• Research
  
  • Forensic and Others
• Clinical
  
  • Pathogen Testing
  • Oncology Testing
  • Blood Screening
  • Others

Global Real-time PCR (qPCR) & Digital PCR (dPCR) Market, By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa (MEA)

The market research study on “Real-time PCR (qPCR) and Digital PCR (dPCR) Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global Real-time PCR (qPCR) & Digital PCR (dPCR) market segments with market dynamics and their impact. The report also covers basic technology development policies.

The report provides an analysis of the latest industry trends from 2015 to 2026 in all sub-segment segments and forecasts revenue and volume growth on the global, the regional and country levels.

An overview of the market and its main concerns is a comprehensive analysis of the global Real-time PCR (qPCR) & Digital PCR (dPCR) market. Market dynamics encompasses drivers, restraints and opportunities to simplify the behavior of the market. A thorough study into the products and geographic segments that would help to understand current market trends is presented in the Section on Market Segmentation.

Key Players & Strategies

Major players in the market have always been focused on implementing strategic commercial measures to maintain their competitive position. New product launches, collaborations and partnerships with institutions and businesses, as well as merger and acquisitions are key measures adopted by the players.

For example, in January 2019, in an agreement worth USD 260 million, FORMULATRIX announced the acquisition of QIAGEN N.V., digital PCR assets. The acquisition will well increase with the strategy of the company to launch new digital PCR platforms in 2020 by using the state-of-the-art dPCR technology of FORMULATRIX.

Some of the prominent competitors dominating the qPCR and dPCR industry include Abbott Laboratories Inc., Bio-Rad Laboratories; Thermo Fisher Scientific Inc.; Agilent Technologies, Inc., Hoffmann La Roche, Qiagen N.V.; and Fluidigm Corporation.